0.0023SEK-14.81%Mkt Cap: 1.64M SEKP/E: —Last update: 2026-05-13
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
P/B0.21
P/S22.11
EV/EBITDA0.27
EV/Revenue-115.92
EPS (TTM)-0.08
EPS (Forward)—
Cash Flow & Leverage
FCF Yield-1346.84%
FCF Margin-29776.52%
Operating CF-35.77M SEK
CapEx (TTM)108.00K SEK
Net Debt/EBITDA0.32
Net Debt-10.21M SEK
Technical
SMA 500.0048 (-52.0%)
SMA 2000.0636 (-96.4%)
Beta0.13
S&P 52W Chg24.23%
Avg Vol (30d)15.39M
Avg Vol (10d)20.51M
Technical Indicators
RSI (14)37.8
MACD-0.0007
MACD Signal-0.0008
MACD Hist.+0.0001
BB Upper0.0045 SEK
BB Middle0.0031 SEK
BB Lower0.0018 SEK
BB Width86.64%
ATR (14)0.0013 SEK
Vol Ratio (20d)0.11x
52W Range
0.00170% of range0.1935
52W High0.1935 SEK
52W Low0.0017 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin-9763.51%
ROE-409.93%
ROA-276.40%
Revenue Growth-94.40%
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio3.15
Quick Ratio3.03
Book Value/Sh0.0130 SEK
Cash/Share0.0170 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.605.93M
Float583.54M
Insiders36.40%
Institutions7.89%
Analyst Consensus
Rating—
Target (Mean)0.0100 SEK
Target Range0.0100 SEK – 0.0100 SEK
# Analysts1
Company
Market Cap1.64M SEK
Enterprise Value-8.58M SEK
Revenue (TTM)74.00K SEK
Gross Profit-22.84M SEK
Net Income (TTM)-32.44M SEK
Revenue/Share0.0000 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees—
Last Price0.0023 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0015382072